Document Detail

Neutralizing capacity of commercial bothropic antivenom against Bothrops jararacussu venom and bothropstoxin-I.
MedLine Citation:
PMID:  11102906     Owner:  NLM     Status:  MEDLINE    
Bothrops jararacussu venom and its major toxin, bothropstoxin-I (BthTX-I), possess myotoxic and neurotoxic activities. The ability of commercial equine antivenom to neutralize these activities was studied in mouse isolated phrenic nerve-diaphragm (PND) and extensor digitorum longus (EDL) preparations by indirect stimulation (0.1 HZ, 0.2 ms). The time required to produce 50% neuromuscular blockade in the PND and EDL preparations was, respectively, 70 +/- 11.5 min and 58 +/- 8 min for B. jararacussu venom (50 microg/mL), and 31 +/- 6 min and 30 +/- 3 min for BthTX-I (20 microg/mL). After a 120-min incubation, the creatine kinase (CK) concentrations in the EDL preparations were 3464 +/- 346 U/L and 3422 +/- 135 U/L following exposure to venom (50 microg/mL) and BthTX-I (20 microg/mL), respectively. Antivenom neutralized the neuromuscular blockade induced by the venom and toxin in PND preparations in a dose-dependent fashion, but only partially neutralized this effect in EDL. Antivenom also effectively prevented the venom- and toxin-induced release of CK from EDL. In contrast, histological analysis showed that the morphological damage caused by B. jararacussu venom and BthTX-I in the EDL was only partially prevented by the anti- venom. These results indicate that commercial equine antiserum fully protects against the neurotoxic action of B. jararacussu and BthTX-I in PND preparations, but only partially protects against the neurotoxic and myotoxic actions of the venom and its toxin in EDL preparations. Care must therefore be exercized in extrapolating results from different preparations even when similar pharmacological or physiological responses are involved.
Y Oshima-Franco; S Hyslop; A C Cintra; J R Giglio; M A da Cruz-Höfling; L Rodrigues-Simioni
Related Documents :
7737266 - Heterozygous familial hypercholesterolaemia is associated with pathological exercise-in...
10413266 - Muscular soreness following prolonged intermittent high-intensity shuttle running.
19574506 - Hormone therapy attenuates exercise-induced skeletal muscle damage in postmenopausal wo...
9130176 - Exercise-induced increase in serum interleukin-6 in humans is related to muscle damage.
11698536 - Distributed motor pattern underlying whole-body shortening in the medicinal leech.
320856 - Quantitative evaluation of vitamin e in the treatment of angina pectoris.
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Muscle & nerve     Volume:  23     ISSN:  0148-639X     ISO Abbreviation:  Muscle Nerve     Publication Date:  2000 Dec 
Date Detail:
Created Date:  2000-12-12     Completed Date:  2000-12-22     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7803146     Medline TA:  Muscle Nerve     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1832-9     Citation Subset:  IM    
Copyright Information:
Copyright 2000 John Wiley & Sons, Inc.
Department of Pharmacology, State University of Campinas, C.P. 6111, CEP 13083-970, Campinas, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antivenins / pharmacology*
Crotalid Venoms / toxicity*
Diaphragm / drug effects,  pathology,  physiology
Electric Stimulation
Muscle, Skeletal / drug effects*,  pathology,  physiology
Neuromuscular Junction / drug effects*,  physiology
Phrenic Nerve / drug effects*,  physiology
Reg. No./Substance:
0/Antivenins; 0/Crotalid Venoms; 116189-59-4/bothropstoxin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mechanomyographic amplitude and mean power output during maximal, concentric, isokinetic muscle acti...
Next Document:  Changes in corticomotor excitability after fatiguing muscle contractions.